← Back to patent-cliff list
129Xe
Tier C — Watch / trade129Xe
Neuroprotexeon Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Updating
Indications (approved)：Pulmonary hypertension, Interstitial lung disease, Systemic sclerosis, Pulmonary fibrosis, Idiopathic pulmonary fibrosis, Radiation injury, COVID-19, 支气管肺发育不良
Regional status
US
Phase II
2013-01-01
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of 129Xe?
Approved indications include: Pulmonary hypertension, Interstitial lung disease, Systemic sclerosis, Pulmonary fibrosis, Idiopathic pulmonary fibrosis, Radiation injury, COVID-19, 支气管肺发育不良.
When does the 129Xe patent expire?
No public expiry year is available for 129Xe yet; this page updates once verified.
How do I get a quote for 129Xe intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-13